Intech Investment Management LLC Sells 4,290 Shares of Hologic, Inc. (NASDAQ:HOLX)

Intech Investment Management LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,196 shares of the medical equipment provider’s stock after selling 4,290 shares during the period. Intech Investment Management LLC’s holdings in Hologic were worth $4,578,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the third quarter worth about $25,000. Innealta Capital LLC acquired a new stake in Hologic during the 2nd quarter valued at approximately $25,000. iA Global Asset Management Inc. bought a new position in Hologic during the 1st quarter worth approximately $37,000. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in shares of Hologic in the 2nd quarter worth approximately $37,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Up 0.3 %

Shares of NASDAQ:HOLX opened at $78.97 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The business’s 50 day simple moving average is $80.44 and its two-hundred day simple moving average is $78.32. The firm has a market cap of $18.34 billion, a P/E ratio of 23.71, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $0.89 EPS. As a group, research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HOLX shares. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Leerink Partners dropped their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Mizuho cut their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.